QUANTUM X LABS INC. quarterly report, Q1 FY2016

Business Context and Reporting Period

Emerald Medical Applications Corp. filed this unaudited Form 10-Q for the quarter ended March 31, 2016. The filing describes a digital health startup developing and commercializing DermaCompare, a skin-imaging and analytics product. The request metadata names QUANTUM X LABS INC.; that does not match the registrant named in the filing.

Financial Results and Position

MetricQ1 2016Q1 2015 / comparison
Revenue$0$0
Operating expenses$1,902,868$178,725
Net loss$1,900,230$180,322
Basic and diluted loss per share$0.11$0.85
Operating cash flow$(173,002)$(127,312)
Financing cash flow$157,250$131,798
Cash at period end$94,859$2,162

At March 31, 2016, total assets were $113,380 and total liabilities were $349,889, including $202,224 of short-term notes payable and $31,157 of convertible notes payable, net of discount. Stockholders’ deficit was $236,509. Cash declined from $115,449 at December 31, 2015. The filing reports no revenue, so a gross margin is not applicable; it provides no clear operating-margin measure.

Material Changes and Financing

  • Net loss rose substantially year over year, primarily as general and administrative expense increased to $1,799,520 from $178,725. Management attributed the increase mainly to merger-related costs and share-based compensation.
  • Research and development expense was $103,348, compared with none in the prior-year quarter.
  • Operating cash use increased to $173,002. Financing provided $157,250, comprising $75,000 from a convertible note and $82,250 from notes payable.
  • The company issued shares and options for services; the cash-flow statement records $1,445,653 of shares and $274,314 of options issued for services.

Outlook, Risks, and Controls

Management said the company may need up to an additional $1.5 million in capital over the next 12 months to implement its business plan and fund operations. The company had no established revenue source to cover operating costs, insufficient cash for its current plan, and negative working capital; the filing states these conditions raise substantial doubt about its ability to continue as a going concern. Management said it was pursuing additional equity financing.

The filing describes planned sales through healthcare organizations, distributors, partners, and direct channels, but provides no revenue guidance or quantified sales forecast. It identifies financing availability and the risks associated with borrowing as concerns. Management concluded disclosure controls and procedures were not effective as of quarter-end. No material changes to internal control over financial reporting were reported. The filing reports no legal proceedings.

Investor Facts to Verify

  • Confirm the issuer identity: the filing is for Emerald Medical Applications Corp., not the company named in the request metadata.
  • Reconcile working capital: the balance sheet’s current assets of $94,859 and current liabilities of $349,889 imply a deficit of $255,030, while MD&A states negative working capital of $236,509, which matches the reported stockholders’ deficit.
  • Assess the company’s ability to secure additional financing and fund operations given the going-concern warning, low cash balance, and short-term obligations.
  • Review the large share-based compensation and merger-related expenses, as well as the terms and maturity of notes payable and convertible debt.
  • Consider the ineffective disclosure controls and the absence of revenue to date.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.